Ret Proto-Oncogene antibody (C-Term)
Quick Overview for Ret Proto-Oncogene antibody (C-Term) (ABIN392039)
Target
See all Ret Proto-Oncogene (RET) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 1063-1093, C-Term
-
Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
Immunogen
- This RET antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1063-1093 amino acids from the C-terminal region of human RET.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
-
Expiry Date
- 6 months
-
-
-
: "siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma." in: Nucleic acids research, Vol. 36, Issue 1, pp. e2, (2008) (PubMed).
-
-
- Ret Proto-Oncogene (RET)
-
Alternative Name
- RET
-
Background
- RET, a member of the cadherin superfamily, is one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This protein plays a crucial role in neural crest development, and the gene can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations i are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma.
-
Molecular Weight
- 124319
-
Gene ID
- 5979
-
NCBI Accession
- NP_065681, NP_066124
-
UniProt
- P07949
-
Pathways
- RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Target
-